NEO 6860

Drug Profile

NEO 6860

Alternative Names: NEO6860; TRPV1 antagonist - NEOMED; Vanilloid receptor 1 ion channel antagonist - NEOMED

Latest Information Update: 20 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca Canada
  • Developer NEOMED
  • Class Analgesics; Antirheumatics; Benzimidazoles; Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Musculoskeletal pain; Neuropathic pain; Visceral pain

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Neuropathic pain; Visceral pain

Most Recent Events

  • 03 Nov 2017 Pharmacokinetics and adverse events data from a phase II trial in Musculoskeletal pain (associated with osteoarthritis of the knee) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 24 Nov 2016 Neomed Institute completes a phase II trial for Musculoskeletal pain (associated with osteoarthritis of the knee) in Canada (PO) (NCT02712957)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top